ZYME Stock Overview
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.30|
|52 Week High||US$39.41|
|52 Week Low||US$4.56|
|1 Month Change||-1.10%|
|3 Month Change||-10.00%|
|1 Year Change||-82.96%|
|3 Year Change||-71.36%|
|5 Year Change||-24.55%|
|Change since IPO||-51.54%|
Recent News & Updates
Zymeworks And The Blue Falcon Elucidation
Zymeworks shares have fallen, but the pipeline remains intact. Moreover, a special situation is brewing. Positive expectation with ZYME.
|ZYME||US Biotechs||US Market|
Return vs Industry: ZYME underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: ZYME underperformed the US Market which returned -18.5% over the past year.
|ZYME Average Weekly Movement||15.0%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ZYME is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ZYME's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Zymeworks Fundamentals Summary
|ZYME fundamental statistics|
Is ZYME overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZYME income statement (TTM)|
|Cost of Revenue||US$217.74m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.15|
|Net Profit Margin||-858.18%|
How did ZYME perform over the long term?See historical performance and comparison
Is ZYME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZYME?
Other financial metrics that can be useful for relative valuation.
|What is ZYME's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ZYME's PS Ratio compare to its peers?
|ZYME PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: ZYME is good value based on its Price-To-Sales Ratio (13x) compared to the peer average (82.8x).
Price to Earnings Ratio vs Industry
How does ZYME's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: ZYME is good value based on its Price-To-Sales Ratio (13x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is ZYME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||13x|
|Fair PS Ratio||0.006x|
Price-To-Sales vs Fair Ratio: ZYME is expensive based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Share Price vs Fair Value
What is the Fair Price of ZYME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZYME's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Zymeworks forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZYME's revenue (51.2% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: ZYME's revenue (51.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZYME is forecast to be unprofitable in 3 years.
Discover growth companies
How has Zymeworks performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZYME is currently unprofitable.
Growing Profit Margin: ZYME is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZYME is unprofitable, and losses have increased over the past 5 years at a rate of 44.7% per year.
Accelerating Growth: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: ZYME has a negative Return on Equity (-84.93%), as it is currently unprofitable.
Discover strong past performing companies
How is Zymeworks's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ZYME's short term assets ($324.0M) exceed its short term liabilities ($80.0M).
Long Term Liabilities: ZYME's short term assets ($324.0M) exceed its long term liabilities ($67.6M).
Debt to Equity History and Analysis
Debt Level: ZYME is debt free.
Reducing Debt: ZYME has no debt compared to 5 years ago when its debt to equity ratio was 8.8%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZYME has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ZYME has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 45.4% each year.
Discover healthy companies
What is Zymeworks's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZYME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZYME's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ZYME has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ken Galbraith (58 yo)
Mr. Kenneth H. Galbraith, also known as Ken, C.A., serves as Chief Executive Officer & Chairman of the Board at Zymeworks Inc since January 15, 2022 and serves as its President since January 15, 2022. He s...
Experienced Management: ZYME's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Experienced Board: ZYME's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ZYME insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.1%.
Zymeworks Inc.'s employee growth, exchange listings and data sources
- Name: Zymeworks Inc.
- Ticker: ZYME
- Exchange: NYSE
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$363.959m
- Shares outstanding: 57.77m
- Website: https://www.zymeworks.com
Number of Employees
- Zymeworks Inc.
- 114 East 4th Avenue
- Suite 800
- British Columbia
- V5T 1G4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.